{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:41:48Z","timestamp":1790361708718,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R124-A7840-15-S2"],"award-info":[{"award-number":["R124-A7840-15-S2"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.radonc.2020.06.046","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T21:19:01Z","timestamp":1593724741000},"page":"236-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome"],"prefix":"10.1016","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-6598","authenticated-orcid":false,"given":"Karin","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja Vestmoe","family":"Maraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Kiil","family":"Berthelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5907-3413","authenticated-orcid":false,"given":"Annika","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"de Nully Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Richter","family":"Vogelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Meidahl","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-2190","authenticated-orcid":false,"given":"Lena","family":"Specht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2020.06.046_b0005","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0010","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: Final analysis of the German Hodgkin study group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0015","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2020.06.046_b0020","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2020.06.046_b0025","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0030","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0025-7125(16)33107-8","article-title":"The treatment of Hodgkin\u2019s disease","volume":"50","author":"Kaplan","year":"1966","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.radonc.2020.06.046_b0035","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin\u2019s lymphoma: Long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0040","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2012.08.041","article-title":"Involved node radiation therapy: an effective alternative in early-stage Hodgkin lymphoma","volume":"85","author":"Maraldo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.06.046_b0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/PPO.0000000000000332","article-title":"Radiotherapy for Hodgkin lymphoma: reducing toxicity while maintaining efficacy","volume":"24","author":"Specht","year":"2018","journal-title":"Cancer J"},{"key":"10.1016\/j.radonc.2020.06.046_b0050","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10147-015-0863-y","article-title":"The concept and evolution of involved site radiation therapy for lymphoma","volume":"20","author":"Specht","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0055","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.93.93","article-title":"Dimension of residual CT scan mass in Hodgkin\u2019s lymphoma (HL) is a negative prognostic factor in patients with PET negative after chemo+\/\u2212 radiotherapy","volume":"118","author":"Magagnoli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2020.06.046_b0060","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.radonc.2014.06.001","article-title":"Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake","volume":"111","author":"Due","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0065","doi-asserted-by":"crossref","DOI":"10.1118\/1.4816308","article-title":"Failure-probability driven dose painting","volume":"40","author":"Vogelius","year":"2013","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2020.06.046_b0070","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s00259-015-3004-y","article-title":"High FDG uptake areas on pre-radiotherapy PET\/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer","volume":"42","author":"Calais","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2020.06.046_b0075","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0080","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0085","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.06.046_b0090","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/JCO.2006.07.0409","article-title":"Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin\u2019s disease","volume":"24","author":"Guadagnolo","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0095","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cncr.28698","article-title":"Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission","volume":"120","author":"Pingali","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2020.06.046_b0100","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0105","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.radonc.2020.06.046_b0110","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0115","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.radonc.2008.05.012","article-title":"The conundrum of Hodgkin lymphoma nodes: To be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines","volume":"88","author":"Girinsky","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0120","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","article-title":"Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2020.06.046_b0125","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/blood.V130.Suppl_1.736.736","article-title":"PET-based response after 2 cycles of brentuximab vedotin in combination with AVD for first-line treatment of unfavorable early-stage Hodgkin lymphoma: first analysis of the primary endpoint of breach, a randomized phase II trial of Lysa-FIL-EORTC Intergro","volume":"130","author":"Fornecker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2020.06.046_b0130","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.2019001272","article-title":"Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2020.06.046_b0135","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL Trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0140","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3324\/haematol.2016.141846","article-title":"Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: Prognostic significance of measurements in the coronal and transverse planes","volume":"101","author":"Kumar","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.radonc.2020.06.046_b0145","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/bloodadvances.2019001023","article-title":"Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I\/IIA Hodgkin lymphoma","volume":"4","author":"Illidge","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.radonc.2020.06.046_b0150","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/0959-8049(92)90243-U","article-title":"Tumour burden as the main indicator of prognosis in Hodgkin\u2019s disease","volume":"28","author":"Specht","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2020.06.046_b0155","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S1053-4296(96)80012-9","article-title":"Prognostic factors in Hodgkin\u2019s disease","volume":"6","author":"Specht","year":"1996","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0160","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/cncr.20568","article-title":"The clinical value of tumor burden at diagnosis in Hodgkin lymphoma","volume":"101","author":"Gobbi","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2020.06.046_b0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.critrevonc.2013.11.002","article-title":"Tumor burden in Hodgkin\u2019s lymphoma: Much more than the best prognostic factor","volume":"90","author":"Gobbi","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2020.06.046_b0170","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2017-04-773838","article-title":"Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation","volume":"131","author":"Akhtari","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2020.06.046_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37197-z","article-title":"A PET radiomics model to predict refractory mediastinal hodgkin lymphoma","volume":"9","author":"Milgrom","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2020.06.046_b0180","first-page":"4","article-title":"Methodological framework for radiomics applications in Hodgkin\u2019s lymphoma","author":"Sollini","year":"2020","journal-title":"Eur J Hybrid Imaging"},{"key":"10.1016\/j.radonc.2020.06.046_b0185","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/5.suppl_1.S7","article-title":"The interrelationship between Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphomas","author":"Jaffe","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2020.06.046_b0190","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose-volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.06.046_b0195","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after hodgkin lymphoma treatment 40-year disease risk","volume":"175","author":"Van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.radonc.2020.06.046_b0200","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2020.06.046_b0205","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ajh.25071","article-title":"Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Ansell","year":"2018","journal-title":"Am J Hematol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020303820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020303820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:08:50Z","timestamp":1779811730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814020303820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":41,"alternative-id":["S0167814020303820"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.06.046","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.06.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}